C
명문제약
017180KOSPI의약품 제조업47.0 / 100
Reference Date: 2026-07-24
Financial Score14.5 / 40
News Sentiment12.5 / 25
Momentum10.0 / 20
Disclosure10.0 / 15
AI Analysis: PBR is significantly undervalued vs. peers but the high debt ratio poses financial risk. Roughly flat over the past month, with no recent news.
Company InformationBased on 2025 Annual Report
Business Overview
Myungmoon Pharmaceutical operates in two main segments: pharmaceutical/biotech and services. The company generates revenue through the production and distribution of key products such as cholesterol treatment medications. In 2025, consolidated sales reached approximately 195,247 million won, showing growth in both domestic and export markets.
Number of Employees
309people
Average Salary
63.1M KRW
Score Calculation Basis
Detailed Financial Score
PER
21.40Industry Average 11.231.5Point
1.9x industry avg (risky)
PBR
0.40Industry Average 0.817.0Point
Half of industry avg (excellent)
ROE
1.37Industry Average 4.011.0Point
Well below industry avg
Debt Ratio
68.58Industry Average 12.430.0Point
5.5x industry avg (risky)
Trend 2023~20255.0 / 10 points
Revenue Growth Rate
2.0 / 3
Avg ▲7.3% (2-year basis)
Operating Profit Growth Rate
3.0 / 3
Avg ▲177.2% (2-year basis)
ROE Trend
0.0 / 4
Avg ROE -2.6% (improving, 3yr)
Detailed News Sentiment
0 totalPositive 0Neutral 0Negative 0
Detailed Momentum
52-week position1.0Point
Near 52w low (3%, downtrend)
Current 1,220Won52-week high 1,94552-week low 1,194
1-month return3.0Point
1m -0.97% (flat)
Volume trend6.0Point
Volume surge
Detailed Disclosure
2 totalPositive 0Neutral 2Negative 0
- Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-07-02
- Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-07-02